重症肝炎(以下简称重肝)是一种常见的严重病症,国外报告病死率高达60～90％。近年来对其治疗虽有较大进展,但仍无特效疗法,凭任何一种药物治疗都是困难的。据国内外许多资料表明,必须早期发现,采取综合性治疗措施,才有可能降低病死率。本文就重肝药物治疗中的若干研究进展作一综述。 一.人工免疫抑制治疗,阻止肝细胞继续坏死重肝的发病机制迄今未明。一般认为与病毒侵入肝细胞的数量多、毒力强有关。但重肝组织损伤並非肝炎病毒在肝细胞内繁殖复制的直接结果,而是通过一系列的免疫反应而产生。Duddly等在对重肝发病机制的研究中,重肝及慢性活动性肝炎(CAH)时,抑制细胞(SC)的功能明显降低。由于SC功能低下,导致强烈的免疫应 Severe hepatitis (hereinafter referred to as liver) is a common serious illness, foreign reported case fatality rate as high as 60 to 90%. In recent years, despite its great progress in treatment, but still no effective treatment, with any kind of drug treatment are difficult. According to many domestic and foreign data show that we must early detection, comprehensive treatment measures, it is possible to reduce mortality. This article reviews the progress of several studies in the treatment of hepatic diseases. One artificial immunosuppressive therapy to prevent liver cells continue to necrosis of the pathogenesis of severe hepatitis so far unknown. Generally believed that the virus invades the number of hepatocytes and more virulent related. However, severe liver injury is not a direct result of hepatitis B virus replication in the liver cells, but through a series of immune responses. Duddly et al. In a study of the pathogenesis of severe hepatitis, the function of inhibitory cells (SCs) was significantly reduced in patients with severe hepatitis and chronic active hepatitis (CAH). Due to SC dysfunction, it leads to a strong immune response